Table 3 of Shpak, Mol Vis 2022; 28:39-47.
Variable | POAG 1–2 subgroup (n=13) | POAG 3–4 subgroup (n=17) | P |
---|---|---|---|
Age | |||
mean±SD | 73.5±5.9 | 74.2±7.9 | |
Range | 62–82 | 57–89 | |
median (IQR) | 72 (69–78) | 73 (71–80) | |
Sex | |||
women, n (%) | 10 (77%) | 11 (77%) | |
IOP, mmHg | |||
mean±SD | 13.3±2.6 | 13.6±3.1 | |
range | 9–18 | 9–19 | |
median (IQR) | 13 (12–15) | 13 (11–16) | |
Medications, n (%) | |||
β-blockers | 10 (77%) | 7 (41%) | (0.071) a |
Prostaglandin analogs | 1 (8%) | 3 (18%) | |
Topical carbonic anhydrase inhibitors | 6 (46%) | 5 (29%) | |
Laser treatment and surgery | |||
SLT | 7 (54%) | 9 (53%) | |
NPDS | 5 (39%) | 13 (76%) | (0.061) a |